FDA Suggests New Flexibility for Blinding Cancer Trials

Drug Industry Daily
Cancer patients in clinical trials should be told whether they’ve been given placebos or experimental drugs if their tumors reappear or get worse—and patients and researchers should be told if sponsors are worried experimental drugs may be triggering bad reactions, the FDA says in new draft guidance released Thursday.

To View This Article:


Subscribe To Drug Industry Daily